首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1548178

全球吸入藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Inhalable Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年08月01日 | 出版商:

Value Market Research | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球吸入藥物市場需求預計將從 2023 年的 392.1 億美元達到近 734.3 億美元的市場規模，2024-2032 年研究期間複合年成長率為 7.22%。

可吸入藥物是設計為透過吸入給藥的藥物，通常透過吸入器或霧化器等裝置。這些藥物被配製為將治療劑直接輸送到呼吸道，在那裡它們可以發揮局部作用，例如減少發炎或擴張氣道。這些藥物通常用於治療氣喘和慢性阻塞性肺病 (COPD) 等慢性呼吸系統疾病，包括多種類別，例如支氣管擴張劑、皮質類固醇和聯合療法。這些藥物的有效性取決於它們是否能精確有效地輸送到肺部，從而提高治療效果並最大限度地減少全身副作用。吸入器技術和藥物配方的創新不斷提高這些治療的功效和便利性，滿足呼吸系統疾病患者的複雜需求。

市場動態

氣喘和慢性阻塞性肺病等慢性呼吸道疾病的發生率不斷上升，推動了吸入藥物市場的發展，這些疾病在不同的人群中普遍存在。人們對非侵入性治療方案的認知和偏好不斷提高，推動了對吸入藥物的需求，因為它們提供具有最小全身影響的標靶治療。吸入器設備的技術進步，包括具有整合數位健康功能的智慧吸入器，透過提高患者依從性和最佳化藥物輸送，為市場成長開闢了新的途徑。此外，對個人化醫療的日益重視以及生物製劑和聯合療法等新型吸入製劑的開發，為市場擴張提供了重大機會。新興市場醫療保健服務的成長以及呼吸系統疾病研究投資的增加進一步促進了市場的成長。加強病患教育和支持計畫也提高了吸入藥物療法的整體有效性和採用率。然而，先進的吸入藥物製劑和設備的高成本可能會抑制吸入藥物市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球吸入藥物市場的各個細分市場進行了包容性評估。吸入藥物產業的成長和趨勢為本研究提供了整體方法。

市場區隔

吸入藥物市場報告的這一部分提供了有關國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人口統計數據以及即將到來的機會。

按藥物類別

氣霧劑
乾粉製劑
噴

按申請

呼吸系統疾病
非呼吸系統疾病

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的吸入藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。吸入藥物市場的主要參與者包括阿斯特捷利康、賽諾菲、Vectura Group Ltd、Viatris Inc.、GSK Plc.、Mundipharma International.、Boehringer Ingelheim International GmbH.、Cipla Inc.。，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：吸入藥品公司的競爭格局

吸入藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
AstraZeneca

公司概況
公司收入
產品
最新動態

Sanofi

公司概況
公司收入
產品
最新動態

Vectura Group Ltd

公司概況
公司收入
產品
最新動態

Viatris Inc.

公司概況
公司收入
產品
最新動態

GSK Plc.

公司概況
公司收入
產品
最新動態

Mundipharma International.

公司概況
公司收入
產品
最新動態

Boehringer Ingelheim International GmbH.

公司概況
公司收入
產品
最新動態

Cipla Inc

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112115512

The global demand for Inhalable Drugs Market is presumed to reach the market size of nearly USD 73.43 Billion by 2032 from USD 39.21 Billion in 2023 with a CAGR of 7.22% under the study period 2024-2032.

Inhalable drugs are medications designed to be administered via inhalation, typically through devices such as inhalers or nebulizers. These drugs are formulated to deliver therapeutic agents directly to the respiratory tract, where they can exert localized effects, such as reducing inflammation or dilating airways. Commonly used in treating chronic respiratory conditions like asthma & chronic obstructive pulmonary disease (COPD), these drugs include various classes, such as bronchodilators, corticosteroids, and combination therapies. The effectiveness of these medications hinges on their ability to achieve precise and efficient delivery to the lungs, thereby enhancing therapeutic outcomes and minimizing systemic side effects. Innovations in inhaler technology and drug formulations continue to advance these treatments' efficacy and convenience, catering to the complex needs of patients with respiratory ailments.

MARKET DYNAMICS

The inhalable drugs market is bolstered by the propelling incidence of chronic respiratory diseases, such as asthma & COPD, which are prevalent across diverse demographics. The increasing awareness & preference for non-invasive treatment options drive demand for inhalable drugs, as they offer targeted therapy with minimal systemic effects. Technological advancements in inhaler devices, including smart inhalers with integrated digital health capabilities, are opening new avenues for market growth by improving patient adherence and optimizing drug delivery. Moreover, the rising emphasis on personalized medicine & the development of novel inhalable formulations, such as biologics and combination therapies, present significant opportunities for market expansion. The growth of healthcare access in emerging markets & the rising investment in respiratory disease research further contribute to the market growth. Increased efforts in patient education and support programs also enhance the overall effectiveness and adoption of inhalable drug therapies. However, the high cost of advanced inhalable drug formulations and devices may restrain inhalable drug market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Inhalable Drugs. The growth and trends of Inhalable Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Inhalable Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Aerosol
Dry Powder Formulation
Spray

By Application

Respiratory Diseases
Non-respiratory Disease

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Inhalable Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Inhalable Drugs market include AstraZeneca, Sanofi, Vectura Group Ltd, Viatris Inc., GSK Plc., Mundipharma International., Boehringer Ingelheim International GmbH., Cipla Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. INHALABLE DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL INHALABLE DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data Analysis By Drug Class
5.3. Aerosol Historic and Forecast Sales By Regions
5.4. Dry Powder Formulation Historic and Forecast Sales By Regions
5.5. Spray Historic and Forecast Sales By Regions

6. GLOBAL INHALABLE DRUGS MARKET ANALYSIS BY APPLICATION

6.1. Overview By Application
6.2. Historical and Forecast Data Analysis By Application
6.3. Respiratory Diseases Historic and Forecast Sales By Regions
6.4. Non-respiratory Disease Historic and Forecast Sales By Regions

7. GLOBAL INHALABLE DRUGS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE INHALABLE DRUGS COMPANIES

8.1. Inhalable Drugs Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF INHALABLE DRUGS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. AstraZeneca
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Sanofi
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Vectura Group Ltd
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Viatris Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. GSK Plc.
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Mundipharma International.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Boehringer Ingelheim International GmbH.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Cipla Inc
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments